I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism

Shanghai 's I-Mab reported China approval to conduct a Phase III trial of  eftansomatropin as a once-weekly treatment for growth hormone deficiency in pediatric patients (PGHD). Eftansomatropin uses Genexine's half-life extension hyFc® fusion technology for its long-acting delivery. Efficacy of weekly or biweekly dosing was comparable to the daily injected rhGH (genotropin). I-Mab acquired China rights to the candidate from Korea 's Genexine. More details.... Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 095700) Share this with colleagues: // //